Parent-drug and active-metabolite exposure can change differently.
Study findings
The PBPK analysis modeled clobazam, N-desmethylclobazam and stiripentol using adult and pediatric data. Predicted metabolite increases with co-treatment differed substantially by CYP2C19 phenotype. Extrapolation to children under two was based on the model rather than a large new trial in that age group.
What limits the conclusion
Sparse pediatric concentration profiles limited validation. Simulated trough ratios are not direct measurements from every patient, and model consistency does not guarantee individual safety. Parent-drug exposure alone may omit an important active component.
Implications for case review
Identify whether a reported value is measured or simulated and which molecular species it concerns. The model cannot reconstruct a person’s genotype, adherence or concentration from the prescription alone. Actual clinical findings and appropriate analyte measurements are needed before attributing symptoms to the interaction.
Source and related reading
Source: PMC12653854, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Clobazam Interaction Review Shows Why Measuring the Active Metabolite Matters.
Leave a Reply